Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 MRSE of Treatment Groups (D)

From: Safety and effectiveness of the SUPRACOR presbyopic LASIK algorithm on hyperopic patients

MRSE Group A
Dominant
(Supracor)
Group A
Non Dominant
(Supracor)
Group B
Dominant
(LASIK)
Group B
Non-Dominant
(Supracor)
Group C
Dominant
(No treatment)
Group C
Non-Dominant
(Supracor)
Pre-Op 1.81 ± 0.32 1.76 ± 0.38 1.63 ± 0.46 1.81 ± 0.72 0.76 ± 0.38 0.78 ± 0.48
1 month −0.39 ± 0.55 −0.51 ± 0.61 −0.16 ± 0.37 −1.06 ± 0.78 0.68 ± 0.44 −0.78 ± 0.59
3 months −0.32 ± 0.40 −0.53 ± 0.42 0.10 ± 0.31 −0.76 ± 0.63 0.66 ± 0.39 −0.51 ± 0.60
6 months −0.47 ± 0.24 −0.59 ± 0.64 0.01 ± 0.21 −0.55 ± 0.63 0.60 ± 0.46 −0.45 ± 0.38